Food and Drug Administration

Company

Last mentioned: Mar 20, 2026

Timeline

  1. Media Backlash

    Health experts and advocacy groups label the bill's scientific claims regarding water pollution as unverified.

  2. Bill Introduction

    Rep. Mary Miller introduces the Clean Water For All Life Act in the House.

  3. Press Conference

    Miller and Kristan Hawkins (Students for Life) present the bill as an environmental protection measure.

  4. Refusal to File

    FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.

  5. Grant Rescissions

    The White House rescinds hundreds of millions in mRNA research funding.

  6. Workaround Support

    FDA officials reportedly signal acceptance of Moderna's alternative trial data submission.

  7. Flu Vaccine Collaboration

    Moderna begins working with the FDA on trial designs for its mRNA flu vaccine.

  8. Peak Valuation

    Moderna reaches a $200 billion market cap following global vaccine success.

Stories mentioning Food and Drug Administration 3

pharma Bearish

GOP Bill Targets Abortion Pill Access via Environmental Water Safety Regulations

House Republicans have introduced the Clean Water For All Life Act, a bill that seeks to restrict abortion pill access by framing fetal remains as environmental pollutants. The legislation would mandate 'catch kits' for patients, ban telehealth prescriptions, and impose severe criminal penalties including five-year prison sentences.

3 sources
regulation Bearish

GOP's 'Clean Water For All Life Act' Targets Abortion Pills via EPA Regulation

House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services.

3 sources
regulation Bearish

FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation

The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.

2 sources